What Is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?

ATTR-CM is a rare and progressive type of amyloidosis that affects the heart. Amyloidosis, which is a buildup of abnormal proteins causing protein deposits that affect organ function, directly impacts ATTR-CM by depositing amyloid protein in the walls of the left ventricle of the heart. As these deposits collect, the heart walls stiffen, causing the left ventricle to struggle with relaxing and filling with blood, as well as failing to pump blood out of the heart. These deposits can thicken and stiffen, potentially causing heart failure. Individuals with ATTR-CM may experience shortness of breath, coughing or wheezing, or swelling in the feet, ankles, and legs, along with other symptoms that can affect the cardiovascular (CV) system.^Footnote1

There are several different treatments for individuals with ATTR-CM that attempt to stop further amyloid formation. Some treatments, like stabilizers, bind to the protein deposits and attempt to stabilize the condition, while others, like gene silencers, slow the liver’s production of faulty amyloid proteins. However, these treatments are only meant to support individuals with ATTR-CM, and no cure yet exists for this disease.

By taking part in a study that is evaluating a potential treatment designed to improve symptoms in individuals with ATTR-CM, participants in the DepleTTR-CM Study could make a difference in the lives of others in the ATTR-CM and CV community. If you’re interested in this important research, we invite you to click the button below to answer some questions and see if you may qualify for participation.

See if you may qualify